Literature DB >> 31498173

The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma: A Reclassification Study by the Spanish Group for Ovarian Cancer Research (GEICO).

Susanna Leskela1,2, Ignacio Romero3, Eva Cristobal1, Belén Pérez-Mies2,4, Juan M Rosa-Rosa2, Ana Gutierrez-Pecharroman4, Almudena Santón2,4, Belén O Gonzalez5, Raquel López-Reig6, David Hardisson7,8, Francisco Vera-Sempere9,10, Carmen Illueca11, Begoña Vieites12, José A López-Guerrero6, José Palacios1,2,4,13, Andrés Poveda14.   

Abstract

The frequency and prognostic significance of the histologic type in early-stage ovarian cancer (OC) is not as well established as in advanced stages. In addition, histologic typing based only on morphologic features may be difficult, especially in high-grade tumors. In this study, we have analyzed a prospective cohort of 502 early-stage OCs to investigate their frequency, immunohistochemical characteristics, and survival of the 5 main histologic types. Histotype was assigned according to not only the morphologic features but also according to the expression pattern of WT1, p53, Napsin A, and progesterone receptors. In addition, an extended panel including p16, β-catenin, HER2, Arid1A, HINF1B, CK7, CDX2, and CK20 was used to refine the diagnosis in difficult cases. In this series, the frequency of the 5 major histologic types was as follows: endometrioid carcinoma, 32.7%; clear cell carcinoma, 25.1%; high-grade serous carcinoma (HGSC), 24.7%; mucinous carcinoma, 10.2%; low-grade serous carcinoma, 4.6%; and others, 2.8%. The combination of morphology and immunohistochemistry allowed the reclassification of 23% of OCs. The lowest concordance was found between samples initially diagnosed as endometrioid, but finally classified as high-grade serous tumors (22% error rate). Endometrioid carcinoma was the most favorable histologic type, whereas HGSC and low-grade serous carcinoma had the worst prognosis. Clear cell carcinoma with abnormal p53 immunostaining pattern also had poor prognosis. Although histologic grade was not a prognostic factor among early-stage endometrioid OCs, distinction between grade 3 endometrioid OC and HGSC is recommended, taking into account differences in prognosis and molecular alterations that can guide different treatments.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31498173     DOI: 10.1097/PAS.0000000000001365

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

Review 1.  Low-grade Serous Tumors: Are We Making Progress?

Authors:  Nina Pauly; Sarah Ehmann; Enzo Ricciardi; Beyhan Ataseven; Mareike Bommert; Florian Heitz; Sonia Prader; Stephanie Schneider; Andreas du Bois; Philipp Harter; Thaïs Baert
Journal:  Curr Oncol Rep       Date:  2020-01-27       Impact factor: 5.075

2.  Differential roles of the Wip1-p38-p53 DNA damage response pathway in early/advanced-stage ovarian clear cell carcinomas.

Authors:  Chenyang Xu; Takeo Minaguchi; Nan Qi; Kaoru Fujieda; Asami Suto; Hiroya Itagaki; Ayumi Shikama; Nobutaka Tasaka; Azusa Akiyama; Sari Nakao; Hiroyuki Ochi; Toyomi Satoh
Journal:  World J Surg Oncol       Date:  2022-04-30       Impact factor: 2.754

3.  Integrative genomics approach identifies molecular features associated with early-stage ovarian carcinoma histotypes.

Authors:  Per Karlsson; Khalil Helou; Hanna Engqvist; Toshima Z Parris; Jana Biermann; Elisabeth Werner Rönnerman; Peter Larsson; Karin Sundfeldt; Anikó Kovács
Journal:  Sci Rep       Date:  2020-05-14       Impact factor: 4.379

Review 4.  A Review of the Clinical Characteristics and Novel Molecular Subtypes of Endometrioid Ovarian Cancer.

Authors:  Shuangfeng Chen; Yuebo Li; Lili Qian; Sisi Deng; Luwen Liu; Weihua Xiao; Ying Zhou
Journal:  Front Oncol       Date:  2021-06-03       Impact factor: 6.244

5.  Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes.

Authors:  Bethany M Barnes; Louisa Nelson; Anthony Tighe; George J Burghel; I-Hsuan Lin; Sudha Desai; Joanne C McGrail; Robert D Morgan; Stephen S Taylor
Journal:  Genome Med       Date:  2021-09-01       Impact factor: 11.117

6.  Napsin A Expression in Human Tumors and Normal Tissues.

Authors:  Sören Weidemann; Jan Lukas Böhle; Hendrina Contreras; Andreas M Luebke; Martina Kluth; Franziska Büscheck; Claudia Hube-Magg; Doris Höflmayer; Katharina Möller; Christoph Fraune; Christian Bernreuther; Michael Rink; Ronald Simon; Anne Menz; Andrea Hinsch; Patrick Lebok; Till Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Eike Burandt; Rainer Krech; David Dum; Till Krech; Andreas Marx; Sarah Minner
Journal:  Pathol Oncol Res       Date:  2021-04-20       Impact factor: 3.201

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.